WebNov 24, 2010 · Genzyme (NASDAQ:GENZ) Share Price and News. Genzyme Corporation is a biotechnology company. The Company’s product and service portfolio is … WebFeb 17, 2011 · Sanofi-Aventis acquired Genzyme for $74 a share, or a total of $20.1 billion plus a contingent value right, in a giant step toward reshaping the company for future …
GENZYME CORPORATION : Stock Price US3729171047
WebApr 8, 2011 · In the merger, each of the remaining shares of Genzyme common stock (other than any shares in respect of which appraisal rights are validly exercised under Massachusetts law and any shares owned by Genzyme, Sanofi-aventis or any of their subsidiaries) were converted into the right to receive the same $74.00 in cash per share … WebAug 29, 2010 · Under the terms of the proposed acquisition, Genzyme shareholders would receive $69 per Genzyme share in cash, representing a 38% premium over Genzyme's … gnuplot stats every
GENZYME CORPORATION : Shareholders Board Members …
WebApr 8, 2011 · The completion came after the successful conclusion of a subsequent offering period relating to sanofi-aventis' exchange offer to acquire all of Genzyme's outstanding shares of common stock for US ... WebThe purchase price represented a 48% premium over Genzyme’s share price of $50 per share immediately preceding the announcement. The acquisition represented the end of a nine-month effort that began on May 23, 2010, when Sanofi CEO Chris Viehbacher first approached Genzyme’s Henri Termeer, the firm’s. founder, and CEO. WebOct 31, 2024 · Genzyme shareholders got one tradable CVR for every share of Genzyme they owned. That FDA approval missed the CVR target date by more than eight months, denying the former Genzyme shareholders a $1 per share payout to add to the $74 they received for the original acquisition. gnuplot set terminal postscript enhanced